SLSara Leite

Sara Leite

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sara Leite has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Histological and haemodynamic characterization of right ventricle in sedentary and trained rats with heart failure with preserved ejection fraction

    by Maria Isilda Oliveira, Sara Leite, António Barros, André P. Lourenço, Cristine Schmidt, Mário Santos, Claúdia Mendes, Adelino Leite-Moreira, Daniel Moreira-Gonçalves

    New Findings What is the central question of this study? Right ventricle (RV) dysfunction is highly prevalent in heart failure with preserved ejection fraction (HFpEF), nearly doubling the risk of death. Knowledge about the RV functional and structural changes in HFpEF and the effect of aerobic exercise is still limited and desirable to expand. What is the main finding and its importance? The HFpEF ZSF1 rat model presents RV structural and functional changes, mimicking the human condition. We show that aerobic exercise prevented the decline in VO2 max, lowered surrogate markers of RV overload (e.g., higher mean and maximum systolic pressure) and improved diastolic dysfunction (e.g., end-diastolic pressure and relaxation time constant). This knowledge emphasizes the importance of using exercise to manage HFpEF. Abstract Background : Right ventricular (RV) dysfunction is highly prevalent in HFpEF and is a marker of poor prognosis. We assessed the ZSF1 obese model of HFpEF to confirm if these rats also develop RV dysfunction and evaluated if aerobic exercise could prevent them. Methods and Results : ZSF1 obese rats were randomly allocated to aerobic exercise training group (n = 7; treadmill running, 5days/week, 60min/day, 15m/min, for 5 weeks) or to a sedentary group (n = 7). We also used ZSF1 lean rats (n = 7) as control group. After 5 weeks, rats were submitted to an exercise tolerance test, invasive hemodynamic evaluation, sacrificed and samples from RV were collected for histologic analysis. ZSF1 obese sedentary rats showed lower VO2 max, RV pressure-overload (e.g., higher mean and maximum systolic pressure) and diastolic dysfunction (e.g. higher minimal and end-diastolic pressurem and relaxation time constant), paralleled by RV cardiomyocyte hypertrophy. Except for cardiomyocyte hypertrophy, aerobic exercise prevented these functional changes.. Conclusions : Our data supports that this model of HFpEF shows functional and structural changes in the RV that resemble the human HFpEF phenotype, reinforcing its utility to understand the pathophysiology and to adress novel therapeutic targets to manage HFpEF. In addition, we show that aerobic exercise is cardioprotective for the RV. A deeper knowledge of the mechanisms underlying the benefits of aerobic exercise could also lead to the identification of therapeutic targets to be further explored. This article is protected by copyright. All rights reserved


  • Chronic Sildenafil Therapy in the ZSF1 Obese Rat Model of Metabolic Syndrome and Heart Failure With Preserved Ejection Fraction

    by Sara Leite, Liliana Moreira-Costa, Rui Cerqueira, Cláudia Sousa-Mendes, António Angélico-Gonçalves, Dulce Fontoura, Francisco Vasques-Nóvoa, Adelino F. Leite-Moreira, André P. Lourenço

    Although decreased protein kinase G (PKG) activity was proposed as potential therapeutic target in heart failure with preserved ejection fraction (HFpEF), randomized clinical trials (RCTs) with type-5 phosphodiesterase inhibitors (PDE5i) showed neutral results. Whether specific subgroups of HFpEF patients may benefit from PDE5i remains to be defined. Our aim was to test chronic sildenafil therapy in the young male ZSF1 obese rat model of HFpEF with severe hypertension and metabolic syndrome. Sixteen-week-old ZSF1 obese rats were randomly assigned to receive sildenafil 100 mg·Kg−1·d−1 dissolved in drinking water (ZSF1 Ob SIL, n = 8), or placebo (ZSF1 Ob PL, n = 8). A group of Wistar-Kyoto rats served as control (WKY, n = 8). Four weeks later animals underwent effort tests, glucose metabolism studies, hemodynamic evaluation, and samples were collected for aortic ring preparation, left ventricular (LV) myocardial adenosine triphosphate (ATP) quantification, immunoblotting and histology. ZSF1 Ob PL rats showed systemic hypertension, aortic stiffening, impaired LV relaxation and increased LV stiffness, with preserved ejection fraction and cardiac index. Their endurance capacity was decreased as assessed by maximum workload and peak oxygen consumption (V˙O2) and respiratory quotient were increased, denoting more reliance on anaerobic metabolism. Additionally, ATP levels were decreased. Chronic sildenafil treatment attenuated hypertension and decreased LV stiffness, modestly enhancing effort tolerance with a concomitant increase in peak, ATP levels and VASP phosphorylation. Chronic sildenafil therapy in this model of HFpEF of the young male with extensive and poorly controlled comorbidities has beneficial cardiovascular effects which support RCTs in HFpEF patient subgroups with similar features.


  • Metformin in non-diabetic patients with metabolic syndrome and diastolic dysfunction: the MET-DIME randomized trial

    by Ricardo Ladeiras-Lopes, Francisco Sampaio, Sara Leite, Diogo Santos-Ferreira, Eduardo Vilela, Adelino Leite-Moreira, Nuno Bettencourt, Vasco Gama, Pedro Braga, Ricardo Fontes-Carvalho

    Purpose Metabolic syndrome (MetS) affects one out of 3 adults in the western world and is associated with preclinical diastolic dysfunction that impairs functional capacity and quality of life (QoL). This randomized trial was designed to evaluate if the addition of metformin to the standard treatment of non-diabetic patients with MetS improves diastolic dysfunction. Methods Prospective, randomized, open-label, blinded-endpoint trial. Fifty-four non-diabetic adults with MetS and diastolic dysfunction were randomized to lifestyle counseling or lifestyle counseling plus metformin (target dose 1000 mg bid). The primary endpoint was the change in mean e’ velocity (assessed at baseline, 6, 12 and 24 months). Secondary endpoints were improvements in insulin resistance, functional capacity and QoL. Linear mixed effects modeling was used for longitudinal data analysis using modified intention-to-treat (mITT) and per-protocol (PP) approaches. Results Forty-nine patients were included in the mITT analysis (mean age = 51.8 ± 6.4; 55% males). Metformin treatment was associated with a significant decrease in HOMA-IR. There was a significantly different mean change in e’ velocity during the study period between trial arms, both in the mITT (at 24 months, change of +0.67 ± 1.90 cm/s in metformin arm vs. −0.33 ± 1.50 cm/s in control arm) and PP populations (+0.80 ± 1.99 cm/s in metformin arm vs. −0.37 ± 1.52 cm/s in control arm), using a random intercept linear mixed model. There were no significant differences in peak oxygen uptake and SF-36 scores between trial arms. Conclusions Treatment with metformin of non-diabetic MetS patients with diastolic dysfunction, on top of lifestyle counseling, is associated with improved diastolic function.


  • Arterial Remodeling and Dysfunction in the ZSF1 Rat Model of Heart Failure With Preserved Ejection Fraction

    by Sara Leite, Rui J. Cerqueira, Jaime Ibarrola, Dulce Fontoura, Amaya Fernández-Celis, Faiez Zannad, Inês Falcão-Pires, Walter J. Paulus, Adelino F. Leite-Moreira, Patrick Rossignol, et al.

    Background: The interplay between the stiffened heart and vessels has long been viewed as a core mechanism in heart failure with preserved ejection fraction, but the incremental vascular molecular remodeling mechanisms from systemic arterial hypertension to heart failure with preserved ejection fraction remain poorly investigated. Our aim was to characterize central arterial remodeling and dysfunction in ZSF1 obese rats and to compare it with hypertensive ZSF1 lean and healthy Wistar-Kyoto controls. Methods and Results: Twenty-week-old male ZSF1 obese (n=9), lean (n=9), and Wistar-Kyoto rats (n=9) underwent left ventricular pressure-volume loop evaluation and synchronous acquisition of ascending aortic flow and pressure. Aortic rings underwent functional evaluation, histology, and molecular biology studies. Although mean arterial pressure, characteristic aortic impedance, and reactivity to phenylephrine were similarly increased in hypertensive ZSF1 lean and obese, only ZSF1 obese showed impaired relaxation and upward-shifted end-diastolic pressure-volume relationships despite preserved systolic function indexes, denoting heart failure with preserved ejection fraction. ZSF1 obese phenotype further showed decreased aortic compliance, increased wave reflection, and impaired direct NO donor and endothelial-mediated vasodilation which were accompanied on structural and molecular grounds by aortic media thickening, higher collagen content and collagen/elastin ratio, increased fibronectin and α-5 integrin protein expression and upregulated TGF (transforming growth factor)-β and CTGF (connective tissue growth factor) levels. Conclusions: Functional, molecular, and structural disturbances of central vessels and their potentially underlying pathways were newly characterized in experimental heart failure with preserved ejection fraction rendering the ZSF1 obese rat model suitable for preclinical testing.


  • P2828Effects of thyroid hormone supplementation on cardiac function in an animal model of HFpEF

    by M Von Hafe, J Sergio Neves, C Vale, G Conceicao, D Miranda-Silva, S Leite, D Fontoura, A Goncalves, J Almeida-Coelho, I Falcao-Pires, et al.

    Background: Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome associated with high morbidity and mortality, for which there is still no effective therapy. Thyroid hormones (TH) have a central role in cardiovascular system homeostasis and their imbalance has been implicated with cardiac dysfunction.

  • 5215Local and systemic hypothyroidism in an animal model of cardiometabolic syndrome and the impact of triiodothyronine supplementation in its metabolic profile

    by C Afonso Couto E Vale, J S Neves, M Von Hafe, G Conceicao, D Fontoura, D Miranda-Silva, S Leite, S Barez-Lopez, M J Obregon, A Goncalves, et al.

    Introduction: Extracardiac comorbidities, including metabolic dysfunction, play an important role in the development and progression of heart failure with preserved ejection fraction (HFpEF). Thyroid hormones have well known metabolic effects. However, the thyroid hormone status and the role of triiodothyronine supplementation in HFpEF remains largely unknown.


  • Chronic exercise induces pathological left ventricular hypertrophy in adrenaline-deficient mice

    by Priscila Mendes, Raquel Martinho, Sara Leite, Leonardo Maia-Moço, Adelino F. Leite-Moreira, André P. Lourenço, Mónica Moreira-Rodrigues


  • Open Access

    P452Chronic exercise training modulates inflammation and reduces left ventricle stiffness in heart failure with preserved ejection fraction

    by C. Schmidt, N. Goncalves, A.F. Silva, J. Coelho, D. Fontoura, S. Leite, D. Miranda-Silva, I. Falcao-Pires, A. Lourenco, J. Oliveira, et al.

    Introduction: Systemic inflammation and endothelial dysfunction have an important role for myocardial dysfunction and remodeling in heart failure with preserved ejection fraction (HFpEF). Microvascular endothelial inflammation leads to increased cardiomyocyte stiffness and interstitial fibrosis which induce diastolic LV dysfunction. Nonetheless, optimal treatment remains widely undefined.

  • Dose–Response Head-to-Head Comparison of Inodilators Dobutamine, Milrinone, and Levosimendan in Chronic Experimental Pulmonary Hypertension

    by Marta Tavares-Silva, Mohamed Alaa, Sara Leite, José Oliveira-Pinto, Lucas Lopes, Adelino F. Leite-Moreira, André P. Lourenço

    The choice of inodilator drug in the acute management of patients with pulmonary hypertension (PH) having right ventricular (RV) failure remains unsettled and challenging. Comprehensive experimental evaluations may provide further insight and fundamental translational research clues to support inodilator selection and clinical trial design. Our aim was to compare acute dose–response hemodynamic effects of inodilators dobutamine (DOB), milrinone (MIL), and levosimendan (LEV) in chronic experimental PH. Seven-week-old male Wistar rats were randomly injected with 60 mg·kg−1monocrotaline (MCT) or vehicle (Ctrl, n = 7) and underwent systemic and pulmonary artery (PA) pressure and RV pressure–volume (PV) hemodynamic evaluation under halogenate anesthesia 24 to 30 days after injection. The MCT-injected animals (n = 7 each) randomly received dose–response infusions of DOB (1, 3, 6 and 12 μg·kg−1·min−1), MIL (MIL: 1, 3, 6 and 12 μg·kg−1·min−1), or LEV (0.3, 0.6, 1.2 and 2.4 μg·kg−1·min−1). Load-independent indexes were obtained by inferior vena cava occlusion at baseline and after the last dose. All inodilators increased RV ejection fraction, preload recruitable stroke work, and ventricular–vascular coupling without jeopardizing perfusion pressure. Dobutamine raised heart rate and PA pressure. Only LEV increased cardiac index and decreased PA elastance and pulmonary vascular resistance (PVR). Moreover, only LEV downward-shifted the end-diastolic PV relationship, thereby improving RV compliance. Adding sildenafil to LEV further decreased PVR. Levosimendan had beneficial acute systolic and diastolic functional effects in experimental chronic PH and RV afterload compared to DOB and MIL. It should be further tested in clinical trials enrolling patients with PH in the perioperative and critical care settings.


  • Characterization of liver changes in ZSF1 rats, an animal model of metabolic syndrome

    by Marta Borges Canha, José Pedro Portela-Cidade, Glória Conceição, Cláudia Sousa-Mendes, Sara Leite, Dulce Fontoura, Daniel Moreira-Gonçalves, Inês Falcão-Pires, André Lourenço, Adelino Leite-Moreira, et al.

    Background: The non-alcoholic fatty liver disease is the hepatic counterpart of the metabolic syndrome. ZSF1 rats are a metabolic syndrome animal model in which liver changes have not been described yet. Aim: The characterization of liver histological and innate immunity changes in ZSF1 rats. Methods: Five groups of rats were included (n = 7 each group): healthy Wistar-Kyoto control rats (Ctrl), hypertensive ZSF1 lean (Ln), ZSF1 obese rats with a normal diet (Ob), ZSF1 obese rates with a high-fat diet (Ob-HFD), and ZSF1 obese rats with low-intensity exercise training (Ob-Ex). The animals were sacrificed at 20 weeks of age, their livers were collected for: a) measurements of the area of steatosis, fibrosis and inflammation (histomorphological analysis); and b) innate immunity (toll-like receptor [TLR] 2, TLR4, peroxisome proliferator-activated receptor. [PPAR.], toll interacting protein [TOLLIP]) and inflammatory marker (tumor necrosis factor-alpha [TNFvs], interleukin 1 [IL-1]) expression analysis by real-time PCR. Results: Ob, Ob-HFD and Ob-Ex were significantly heavier than Ln and Ctrl animals. Ob, Ob-HFD and Ob-Ex animals had impaired glucose tolerance and insulin resistance. ZSF1 Ob, ObHFD and Ob-Ex presented a higher degree of steatosis (3,5x; p < 0.05) than Ctrl or ZSF1 Ln rats. Steatohepatitis and fibrosis were not observed in any of the groups. No differences in expression were observed between Ctrl, Ln and Ob animals (except for the significantly higher expression of TOLLIP observed in the Ob vs Ln comparison). Ob-HFD and Ob-Ex rats showed increased expression of PPAR. and TOLLIP as compared to other groups. However, both groups also showed increased expression of TLR2 and TLR4. Nevertheless, this did not translate into a differential expression of TNFa or IL-1 in any of the groups. Conclusion: The ZSF1 model is associated with liver steatosis but not with steatohepatitis or a significantly increased expression of innate immunity or inflammation markers.